Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kaleido Biosciences Inc.

kaleido.com

Latest From Kaleido Biosciences Inc.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Financing Innovation

Tech Transfer Roundup: Trio Of Deals Bolster Spherix’s Cancer Strategy

The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.

Deals Research and Development Strategies

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.

Financing StartUps and SMEs

IPO Update: Gottlieb’s Resignation Pulls Down Five Of Eight Newly Public Biopharmas

There have been eight US biopharma IPOs in 2019, but only three are trading above their launch price – a big change from just three days ago.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Kaleido Biosciences Inc.
  • Senior Management
  • Alison Lawton, Pres. & CEO
    Johan van Hylckama Vlieg, PhD, CSO
    John W Davies, PhD, CTO
    Katharine Knobil, MD, Head, R&D & CMO
    Clare Fisher, CBO
  • Contact Info
  • Kaleido Biosciences Inc.
    Phone: (617) 674-9000
    65 Hayden Ave.
    Lexington, MA 02421
    USA
UsernamePublicRestriction

Register